Skip to search formSkip to main contentSkip to account menu

Recurrent Glioblastoma

The reemergence of glioblastoma after a period of remission.
National Institutes of Health

Related topics

Related topics

14 relations
AnaplasiaAstrocytesCentral Nervous SystemGrade four rank

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and survival in recurrent glioblastoma.
2044Background: Glioblastoma (GBM) is an aggressive brain tumor affecting ~74,000 people worldwide annually. Recurrent GBM… 
2010
2010
A phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma.
TPS150 Background: Combination therapy consisting of bevacizumab and irinotecan represents a commonly applied regimen in the… 
2008
2008
A phase I trial of gefitinib and sirolimus in adults with recurrent glioblastoma multiforme (GBM)
2088 Background: Glioblastoma multiforme (GBM) overexpresses the epidermal growth factor receptor (EGFR) and gefitinib is an EGFR… 
2008
2008
Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme
2051 Background: The hepatocyte growth factor/scatter factor (HGF/SF) and its receptor c-Met are implicated in the pathogenesis… 
2008
2008
Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan
13013 Background: Glioblastoma multiforme (GBM) is characterized by diffuse parenchymal infiltration and regional angiogenesis… 
2008
2008
Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme
13008 Background: Bevacizumab, a neutralizing monoclonal antibody to vascular endothelial growth factor (VEGF), has demonstrated… 
Review
2008
Review
2008
Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM)
2028 Background: BEV has shown promise for recurrent GBM in phase II trials. However, the patterns of relapse and prognosis of… 
2008
2008
Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM)
2062 Background: Erlotinib, an EGF receptor kinase inhibitor, has limited single-agent activity in recurrent GBM patients. The… 
2006
2006
A stratified phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: Preliminary results.
1558 Background: The Epidermal Growth Factor Receptor (EGFR) gene is frequently amplified and mutated in high-grade gliomas. We… 
Review
2005
Review
2005
N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis
1505 Background: CCI-779 is a small molecule inhibitor of the mammalian target of rapamycin (mTOR), and represents a rational… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)